TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35048770

Group type: EXPERIMENTAL
Intervention: Anabolic steroids, physiotherapy, and nutritional supplement
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supervised outpatient rehabilitation with individually structured progressive strength training
Number of subjects: 19
Study: 33245144

Group type: EXPERIMENTAL
Intervention: Mobile technology intervention (unidirectional text message reminders)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no mobile technology intervention)
Number of subjects: 220
Study: 35040594

Group type: EXPERIMENTAL
Intervention: Twice daily nasal irrigation with Johnson and Johnson's Baby Shampoo (J&J) in hypertonic saline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hypertonic saline alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 72
Study: 33400436

Group type: EXPERIMENTAL
Intervention: Topical morphine (10 mg) with intrasite gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical loperamide (dose not specified) with intrasite gel
Number of subjects: 0
Study: 35147085

Group type: EXPERIMENTAL
Intervention: Target-controlled plasma infusion of lidocaine (3 mg/L) during induction and maintenance of anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 80
Study: 34726026

Group type: EXPERIMENTAL
Intervention: Qiang Jin exercises, performed one time each morning and evening, 10 sets each time for 12 weeks.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Classic rehabilitation training, performed twice a week for 12 weeks.
Number of subjects: 98
Study: 35866633

Group type: EXPERIMENTAL
Intervention: Marburg virus vaccine candidates
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20000
Study: 33280990

Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wide-head screws
Number of subjects: 10
Study: 35583217

Group type: EXPERIMENTAL
Intervention: Turner syndrome patients (TS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Turner syndrome patients (TS) with orthodontic treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (girls without TS)
Number of subjects: 70
Study: 34813098

Group type: EXPERIMENTAL
Intervention: Deep breathing treatment video
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group (informational video)
Number of subjects: 342
Study: 33010325

Group type: EXPERIMENTAL
Intervention: Omiganan 2.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Omiganan 1% and 1.75%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 80
Study: 34324798

Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention, delivered over 12 weeks via phone.
Number of subjects: 11
Study: 36446460

Group type: EXPERIMENTAL
Intervention: Bi-atrial ablation
Number of subjects: 320

Group type: COMPARATOR
Intervention: Left atrial ablation
Number of subjects: 320
Study: 33210302

Group type: EXPERIMENTAL
Intervention: Low-dose tocilizumab (40 to 200 mg, with allowance for one repeat dose at 24 to 48 hours)
Number of subjects: 32
Study: 35279081

Group type: EXPERIMENTAL
Intervention: Guideline-based therapy with amikacin liposome inhalation suspension
Number of subjects: 71

Group type: COMPARATOR
Intervention: Guideline-based therapy without amikacin liposome inhalation suspension
Number of subjects: 71
Study: 33487590

Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention promoting vegetable intake
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297
Study: 35752527

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 34933416

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (testosterone undecanoate injection three times/6 months, n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo injections (n=21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 41
Study: 33862636

Group type: EXPERIMENTAL
Intervention: Surgical resection of pulmonary metastases of urothelium carcinoma
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Univariate analysis of relapse-free interval
Number of subjects: 139
Study: 32764524

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 36054449

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33439274

Group type: EXPERIMENTAL
Intervention: Structured reporting with digital solutions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard reporting without structured solutions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall evaluation of reports
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Individual departments
Number of subjects: 70
Study: 35727760

Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in SAVOR-TIMI 53 trial
Number of subjects: 10555

Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in CPRD-DM2 cohort
Number of subjects: 10555

Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in CPRD-HT cohort
Number of subjects: 10555
Study: 33124470

Group type: EXPERIMENTAL
Intervention: Experimental condition (watching a video of a socially anxious presenter)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control condition (watching a video of a nonanxious presenter)
Number of subjects: 128
Study: 34425554

Group type: EXPERIMENTAL
Intervention: SC79 injection at 0.02 mg/kg bodyweight
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SC79 injection at 0.04 mg/kg bodyweight
Number of subjects: 78

Group type: COMPARATOR
Intervention: SC79 injection at 0 mg/kg bodyweight (control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SC79 injection
Number of subjects: 78
Study: 32043762

Group type: EXPERIMENTAL
Intervention: Professional oral care (POC)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Number of subjects: 175
Study: 34294123

Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 454

Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 454
Study: 36286977

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with specialized food (2 portions of SPP2 a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric diet alone (ICD)
Number of subjects: 0
Study: 33678517

Group type: EXPERIMENTAL
Intervention: Horizons + Group Motivational Enhancement Therapy
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Horizons
Number of subjects: 560
Study: 35108669

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study: 37151132

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 34454754

Group type: EXPERIMENTAL
Intervention: High-fat milk replacer (HF; 39.9% lactose, 24.6% crude fat, and 24.0% crude protein of dry matter)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-fat milk replacer (HF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-lactose milk replacer (46.1% lactose, 18.0% crude fat, and 23.9% crude protein of dry matter)
Number of subjects: 34
Study: 35309062

Group type: EXPERIMENTAL
Intervention: Unilateral concentric‐only (CONC) training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eccentric‐only (ECC) training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concentric–eccentric (TRAD) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study: 34787844

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33737628

Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeast (C. tropicalis KKU20)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeast (P. kudriavzevii KKU20)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Crabtree-positive yeast (S. cerevisiae)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeasts (P. kudriavzevii KKU20 and C. tropicalis KKU20)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C. tropicalis KKU20
Number of subjects: 6
Study: 32723609

Group type: EXPERIMENTAL
Intervention: Robotic adrenalectomy (RA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy (LA)
Number of subjects: 140
Study: 36443678

Group type: EXPERIMENTAL
Intervention: Artificial neural network (multi-layer perceptron)
Number of subjects: 58
Study: 32915962

Group type: EXPERIMENTAL
Intervention: MR-Clust algorithm for clustering genetic variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MR-Clust algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variants in the cluster with a negative effect of blood pressure
Number of subjects: 0
Study: 36093398

Group type: EXPERIMENTAL
Intervention: VIP future care
Number of subjects: 163

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 163
Study: 33296688

Group type: EXPERIMENTAL
Intervention: Higher-dose NOACs
Number of subjects: 77282

Group type: EXPERIMENTAL
Intervention: Lower-dose NOACs
Number of subjects: 77282

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 77282
Study: 32497453

Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Narrative group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 34737220

Group type: COMPARATOR
Intervention: Oral corticosteroids (OCS) treatment
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Plasma proteomic panel
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Consensus clustering of U-BIOPRED protein data
Number of subjects: 525
Study: 33130236

Group type: EXPERIMENTAL
Intervention: Broad consent for randomization shortly after cohort enrollment
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Broad consent for randomization after randomization to an intervention (12-18 months after cohort enrollment)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Patients not selected for interventions (1-6 months after cohort enrollment)
Number of subjects: 610
Study: 33172395

Group type: EXPERIMENTAL
Intervention: UDCA + CBD stenting
Number of subjects: 64

Group type: COMPARATOR
Intervention: CBD stenting (control)
Number of subjects: 64
Study: 34939318

Group type: EXPERIMENTAL
Intervention: Advised to hand express for 10 minutes twice daily until birth (n=319)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Usual care (not expressing, n=316)
Number of subjects: 635
Study: 32024506

Group type: EXPERIMENTAL
Intervention: You-CAN led by school staff
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: You-CAN led by school staff and research team
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated comparison group
Number of subjects: 3
Study: 32955966

Group type: EXPERIMENTAL
Intervention: Integrated Employment Success Tool (IESTTM)
Number of subjects: 29
Study: 33909947

Group type: EXPERIMENTAL
Intervention: insoluble cereal fibre
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 36030971

Group type: EXPERIMENTAL
Intervention: APEX: 5.25%‐6% NaOCl, 5.25%‐6% NaOCl + 17% EDTA and calcium hydroxide
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: REGEN: 1.25% NaOCl, 17% EDTA, and 0.1 mg/mL triple antibiotic paste (TAP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: REVASC: 5.25% NaOCl, saline, and 1 g/mL TAP
Number of subjects: 97
Study: 33242163

Group type: EXPERIMENTAL
Intervention: Loco-regional treatment (LRT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Systemic treatment (ST)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Stage I–III BC patients
Number of subjects: 81
Study: 32400210

Group type: EXPERIMENTAL
Intervention: Nesplora Aquarium test (experimental group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 32500212

Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, 30 mg/70 kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) (400 mg/70 kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 36277940

Group type: EXPERIMENTAL
Intervention: Personalized home-based support including monthly visits focused on nutritional counseling and pregnancy monitoring.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control group receiving prenatal care according to national program guidelines.
Number of subjects: 617
Study: 33154182

Group type: EXPERIMENTAL
Intervention: Listen-In therapy (self-led therapy app)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 35
Study: 36280985

Group type: EXPERIMENTAL
Intervention: Positional release of subscapularis technique (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ola Grimsby technique (Group B)
Number of subjects: 34
Study: 33910395

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback (SC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Yoked feedback (YK)
Number of subjects: 24
Study: 36102434

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 36
Study: 34560869

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 62
Study: 32087282

Group type: EXPERIMENTAL
Intervention: Down-Regulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Emotional Awareness
Number of subjects: 76

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 76
Study: 33581839

Group type: EXPERIMENTAL
Intervention: Mayo Delirium Prediction (MDP) tool using derivation cohort
Number of subjects: 120764

Group type: EXPERIMENTAL
Intervention: Mayo Delirium Prediction (MDP) tool using validation cohort
Number of subjects: 120764

Group type: EXPERIMENTAL
Intervention: Risk classification based on predicted probability of delirium
Number of subjects: 120764
Study: 33269836

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (once daily for 10 courses, 6 consecutive times each course) at points Quchi (LI11), Zusanli (ST36), Taichong (LR3), Hegu (LI4), Shenshu (BL23), Geshu (BL17), and Dazhui (GV14)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methotrexate (10-15 mg/time, once a week for 10 weeks)
Number of subjects: 120
Study: 33757591

Group type: EXPERIMENTAL
Intervention: Motherly smartphone app with behavioral activation (BA) and brief CBT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simplified version of the Motherly app (active control)
Number of subjects: 70
Study: 33045193

Group type: EXPERIMENTAL
Intervention: Oral-fluid HIV self-tests distributed during home visits; one present household member trained on self-test use.
Number of subjects: 7816

Group type: COMPARATOR
Intervention: Control group referred absent or declining household members to the clinic for HIV testing.
Number of subjects: 7816

Group type: EXPERIMENTAL
Intervention: Intervention group with oral-fluid HIV self-tests.
Number of subjects: 7816

Group type: COMPARATOR
Intervention: Control group without self-tests.
Number of subjects: 7816
Study: 32291095

Group type: EXPERIMENTAL
Intervention: pH-modified moisturizer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard moisturizer
Number of subjects: 36
Study: 35588553

Group type: EXPERIMENTAL
Intervention: Placebo intervention (sham analgesic cream) applied before and after heat stimulations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Heat stimulations applied to the desired and undesired leg
Number of subjects: 19
Study: 32571773

Group type: EXPERIMENTAL
Intervention: Usual care plus oseltamivir
Number of subjects: 308

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 308
Study: 35093029

Group type: EXPERIMENTAL
Intervention: 2 g oral dose of intra-partum azithromycin
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study: 33539944

Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg, D3-D23 of each 28-day cycle) plus paclitaxel (80 mg/m2, D1, 8, and 15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel (80 mg/m2, D1, 8, and 15)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cobimetinib plus atezolizumab (840 mg, D1 and D15) and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cobimetinib plus atezolizumab (840 mg, D1 and D15) and nab-paclitaxel (100 mg/m2, D1, D8, and D15)
Number of subjects: 0
Study: 32888898

Group type: EXPERIMENTAL
Intervention: Self-management program for knee osteoarthritis (8 weeks duration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 33826756

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 0
Study: 33421263

Group type: EXPERIMENTAL
Intervention: Discharge Summaries (DS)
Number of subjects: 100
Study: 32238947

Group type: EXPERIMENTAL
Intervention: WellNet (patient-centered medical home model)
Number of subjects: 5684

Group type: COMPARATOR
Intervention: Standard care (usual care)
Number of subjects: 5684
Study: 36351725

Group type: EXPERIMENTAL
Intervention: MRI arm
Number of subjects: 525

Group type: COMPARATOR
Intervention: PSA arm
Number of subjects: 525
Study: 35488544

Group type: EXPERIMENTAL
Intervention: HEV vaccine administered at 0, 1, and 6 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine diagnosis and treatment without vaccine (Control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HEV vaccine (3 doses)
Number of subjects: 105
Study: 32304484

Group type: EXPERIMENTAL
Intervention: AutonoMe (system A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UltraSert (system U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tecnis iTec (system T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vivinex iSert (system V)
Number of subjects: 0
Study: 35089384

Group type: EXPERIMENTAL
Intervention: Isometric wall squat (IWS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isometric handgrip (IHG)
Number of subjects: 26
Study: 34274786

Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use for more than 180 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use of 180 > cDDD ? 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use of cDDD ? 180
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study: 33844622

Group type: COMPARATOR
Intervention: Expectation Only
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Empathic Support + Expectation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 32519238

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 22
Study: 32883241

Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 162

Group type: COMPARATOR
Intervention: 25-gauge needle
Number of subjects: 162
Study: 35438829

Group type: EXPERIMENTAL
Intervention: Prediction models based on serum biomarkers for sarcopenia
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Cystatin C, estimated glomerular filtration rate based on cystatin C, sarcopenia index, new sarcopenia index, haemoglobin, and albumin levels
Number of subjects: 212
Study: 32384143

Group type: EXPERIMENTAL
Intervention: Smaller global cortical thickness
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Smaller mean thickness in widespread regions
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Smaller thickness in a few frontal and temporal regions
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Right cuneus thickness
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Smaller thickness ratio in frontal and temporal regions
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Greater thickness ratio in the anterior cingulate
Number of subjects: 350
Study: 35986273

Group type: EXPERIMENTAL
Intervention: Digitally supported clinical decision support system for polypharmacy management
Number of subjects: 198
Study: 33278331

Group type: EXPERIMENTAL
Intervention: Wearable Injector (WI) delivering 5 mL subcutaneous placebo injections
Number of subjects: 52
Study: 33028588

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT, n=400)
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT, n=387)
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Control group (n=780)
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: HIIT compared with MICT
Number of subjects: 1567
Study: 36036856

Group type: EXPERIMENTAL
Intervention: PL‐ASA (phospholipid‐aspirin liquid filled capsules)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PL‐ASA
Number of subjects: 36

Group type: COMPARATOR
Intervention: EC‐ASA (low dose enteric-coated aspirin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: EC‐ASA
Number of subjects: 36
Study: 32843241

Group type: EXPERIMENTAL
Intervention: Cash plus intervention
Number of subjects: 1933
Study: 35726631

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study: 32023293

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin-piperaquine and single low-dose primaquine
Number of subjects: 3790
Study: 36430097

Group type: EXPERIMENTAL
Intervention: Yoga-based mindfulness intervention (YBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psycho-educational sessions (Control)
Number of subjects: 0
Study: 32297786

Group type: EXPERIMENTAL
Intervention: 1 mg/kg long‐acting methylphenidate
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 2 mg/kg long‐acting methylphenidate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82